drug_type
RELEVANT_DRUG
intervention_type
Bispecific monoclonal antibody T-cell engager (biologic immunotherapy)
drug_description
A subcutaneous bispecific monoclonal antibody (CD20xCD3) T-cell engager that binds CD20 on malignant B cells and CD3 on endogenous T cells to form an immune synapse, activate TCR/CD3 signaling, and induce T-cell mediated cytotoxicity, resulting in depletion of CD20-positive lymphoma cells.
nci_thesaurus_concept_id
C129691
nci_thesaurus_preferred_term
Mosunetuzumab
nci_thesaurus_definition
A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T-cells and CD20-expressing tumor B-cells; this cross-links T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.
drug_mesh_term
Mosunetuzumab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Bispecific CD20xCD3 monoclonal antibody that simultaneously binds CD20 on malignant B cells and CD3 on endogenous T cells to create an immune synapse, activate TCR/CD3 signaling, and drive T cell–mediated cytotoxic killing and depletion of CD20-positive lymphoma cells.
drug_name
Mosunetuzumab
nct_id_drug_ref
NCT05849857